Compound ID | 400
Synonym(s): CTA A1 | MDL 62,873 | MDL 62873 | CTA-A-1
Class: Glycopeptide
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against oxacillin-resistant and -susceptible Staphylococcus aureus |
| Description: | Semisynthetic compound; an amide derivative of teicoplanin A2-2 |
| Institute where first reported: | Biosearch Italia (Pfizer, US); Aventis (Sanofi Aventis, France) |
| Year first mentioned: | 1988 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| Reason dropped: | Literature papers stop at 1992 which concludes with a need to carry out more pharmacological studies to progress to clinical trials. The study on PMN activity shows that for interference, a dosage higher than proposed human dosage is required. There may be a cross resistance issue but not stated. |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/16132175 |
| Guide to Pharmacology: | mideplanin |
| Citations: |
|